Contact Sales
.

Gain visibility and control over 340B

Changes to the Public Health Service Act 340B Drug Pricing Program have led to an increase in the number of covered entities and contract pharmacies and more stringent financial and legal implications for price errors.
To protect revenue streams and ensure compliance, participating pharmaceutical manufacturers need to effectively manage pricing, rebates, and chargebacks.

Read the white paper to learn best practices for:

  • Chargeback processing
  • Correctly calculating 340B pricing
  • Preventing duplicate discount

The value of outsourcing

14%

of U.S. drug purchases are through the 340B program

4,228%

increase in covered pharmacy participation from 2010 to 2020

35%

of prescriptions audited by HRSA between 2012 and 2019 received a duplicate discount

cta

Powering Innovators

Enabling our Customers to Deliver Life-Changing Products to the World

Close